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Indrani Talukdar, Wioletta Szeszel-Fedorowicz, and Lisa M. Salati1
From the Department of Biochemistry and Molecular Pharmacology, West Virginia University, Morgantown, West Virginia 26506
Polyunsaturated fatty acids are potent inhibitors of lipogenic
gene expression in liver. The lipogenic enzyme glucose-6-phosphate dehydrogenase (G6PD) is unique in this gene family, in that
fatty acids inhibit at a post-transcriptional step. In this study, we
have provided evidence for a signaling pathway for the arachidonic
acid inhibition of G6PD mRNA abundance. Arachidonic acid
decreases the insulin induction of G6PD expression; by itself,
arachidonic acid does not inhibit basal G6PD mRNA accumulation.
The insulin stimulation of G6PD involves the phosphoinositide
3-kinase (PI 3-kinase) pathway (Wagle, A., Jivraj, S., Garlock, G. L.,
and Stapleton, S. R. (1998) J. Biol. Chem. 273, 14968 –14974). Incubation of hepatocytes with arachidonic acid blocks the activation of
PI 3-kinase by insulin as observed by a decrease in Ser473 phosphorylation of Akt, the downstream effector of PI 3-kinase. The
decrease in PI 3-kinase activity was associated with an increase in
Ser307 phosphorylation of IRS-1. Western analysis demonstrated
increased phosphorylation of p38 mitogen-activated protein kinase
(MAPK) in arachidonic acid-treated cells, whereas extracellular signal-regulated kinase and c-Jun NH2-terminal kinase activity was
not changed. Incubating the hepatocytes with the p38 MAPK inhibitor, SB203580, blocked the arachidonic acid inhibition of G6PD
mRNA accumulation. Furthermore, SB203580 decreased the
arachidonic acid-mediated Ser307 phosphorylation of IRS-1 and
rescued Akt activation that was otherwise decreased by arachidonic
acid. Thus, arachidonic acid inhibits the insulin stimulation of
G6PD mRNA accumulation by stimulating the p38 MAPK pathway,
thereby inhibiting insulin signal transduction.

Insulin is the central hormone required for the activation of lipogenic
genes in the liver. Feeding animals a high carbohydrate diet enhances
the expression of the lipogenic genes. This effect involves the stimulatory actions of both dietary glucose and insulin (1, 2). In contrast, dietary
polyunsaturated fats attenuate the stimulatory effect of feeding a high
carbohydrate diet (3, 4). We have used glucose-6-phosphate dehydrogenase (G6PD),2 a member of the lipogenic gene family, as a model
system for studying the mechanism of action of fatty acids. The advantage of this model is that insulin is the primary inducer of G6PD expression, and fatty acids such as arachidonic acid are the primary inhibitors
of G6PD expression; this regulation is independent of other hormonal
requirements (5, 6). The intracellular mechanisms by which polyunsat-
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urated fats inhibit G6PD or other lipogenic genes are not completely
understood. Inhibition by polyunsaturated fatty acid may represent a
direct action of fatty acids on factors involved in gene expression. Alternatively, fatty acids may act indirectly via the inhibition of stimulatory
signal transduction pathways of glucose or insulin. We hypothesized
that fatty acids inhibit G6PD expression by inhibition of the insulin
induction.
Insulin transduces its signal upon binding to the insulin receptor.
Transduction of this signal in liver involves phosphorylation of two
intracellular substrates, insulin receptor substrate (IRS)-1 and IRS-2 (7).
These proteins play complementary roles in insulin signaling (8). Activation of phosphoinositide (PI) 3-kinase is associated with the stimulatory effects of insulin on metabolic pathways, including lipogenesis
(9 –11).
The IRS proteins can be phosphorylated on both tyrosines and
serines. A known mechanism for the inhibition of IRS-1 activation is by
phosphorylation at serines 307, 612, and 632 (12). These serine residues,
when phosphorylated might interfere with the interaction between
IRS-1 and the insulin receptor or PI 3-kinase (13, 14). Among the factors
known to cause serine phosphorylation of IRS-1 are the mitogen-activated protein (MAP) kinases. Activation of the MAP kinases extracellular regulated kinase (ERK) (15, 16), c-Jun NH2-terminal kinase (JNK)
(17–19), or p38 MAP kinase (MAPK) (17, 20) is associated with the
development of insulin resistance in muscle and adipose tissue.
Known activators of MAP kinases include tumor necrosis factor ␣
(TNF␣) and very high fat diets. TNF␣, a potent mediator of insulin
resistance, activates all three of the MAP kinases. Phosphorylation and
activation of p38 MAPK by TNF␣ correlates with IRS-1 serine phosphorylation and a decrease in PI 3-kinase activity (17, 20). In muscle and
adipose tissue, this results in the decrease in glucose uptake associated
with insulin resistance. Likewise, diets containing 40% or more of the
energy content as fat also decrease PI 3-kinase activation and result in an
insulin-resistant phenotype in intact animals (21–23). This may involve
activation of MAP kinases (18, 19). In contrast to the pathological effects
of large amounts of dietary fat, the addition of smaller amounts of polyunsaturated fat (⬍20% of energy) to a high carbohydrate diet has a
potent but reversible inhibitory effect on lipogenic gene expression (3).
The question remains whether modulation of insulin signaling by low
levels of dietary fat is involved in the non-pathological regulation of
metabolic pathways and, in particular, the de novo synthesis of fatty
acids.
In this paper, we have reported a signaling pathway by which polyunsaturated fatty acids inhibit G6PD expression. We have demonstrated
that arachidonic acid inhibits the insulin-mediated induction of G6PD
mRNA abundance in primary rat hepatocytes. This inhibition of insulin
action occurs by Ser307 phosphorylation of IRS-1. Incubation of hepatocytes with arachidonic acid results in an activation of p38 MAPK,
thereby inducing IRS-1 serine phosphorylation and reducing PI 3-kinase activation. Inhibition of p38 MAPK results in a loss of the arachidonic acid-mediated inhibition of G6PD expression. This is the first
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report of p38 MAPK involvement in the regulation of a lipogenic gene
by polyunsaturated fatty acids.

EXPERIMENTAL PROCEDURES
Animal Care and Cell Culture—Male Sprague-Dawley rats (175–225
g) were starved 16 h prior to surgery. Hepatocytes were isolated by a
modification of the technique of Seglen (24) as previously described (6).
Hepatocytes (3.1 ⫻ 106) were placed in 60-mm dishes coated with rat
tail collagen and incubated in Hi/Wo/Ba medium (Waymouth
MB752/1 plus 20 mM HEPES, pH 7.4, 0.5 mM serine, 0.5 mM alanine,
0.2% bovine serum albumin). The medium containing the treatments
indicated in the figure legends was added after 24 h in culture. Fatty
acids (Nu-Check Prep) were added as a complex bound to bovine serum
albumin (25). The fatty acid (4 mM) albumin (1 mM) stocks contained
butylated hydroxytoluene (0.1%), and the medium contained ␣-tocopherol phosphate, disodium (10 g/liter) to minimize oxidation of fatty
acids. The concentration of arachidonic acid used (175 M) resulted in
the maximum inhibition of G6PD expression (6, 26). Hepatocytes not
receiving arachidonic acid were treated with an equivalent amount of
albumin and butylated hydroxytoluene. Because arachidonic acid is
metabolized rapidly by the hepatocytes, the medium was replenished
every 12 h. The ERK inhibitor (PD98059) was purchased from Cell
Signaling Technology; the inhibitors of PI 3-kinase (LY294002) and p38
MAPK (SB203580) were purchased from Calbiochem.
Isolation of Total RNA and Ribonuclease Protection Assay—Total
RNA from 2–3 plates/treatment was isolated by the method of Chomczynski and Sacchi (27). Quantitation of RNA was performed using
RNase protection assays (Ambion, Inc.). Rat G6PD exon 13 template
was synthesized as described previously (26). The templates for the rat
␤-actin and 18S probes were purchased from Ambion, Inc. Probe synthesis, hybridizations, and RNase digestion were as previously described
(28). The resulting hybridization products protected from RNase digestion were separated in a 5% denaturing polyacrylamide gel. Images were
visualized by storage phosphor technology and quantified using ImageQuant software by Amersham Biosciences.
Preparation of Cell Extract and Western Blot Analysis—The hepatocytes were lysed in buffer containing 10 mM Tris, pH 7.4, and 1% SDS,
and total protein was quantified using a BCA protein assay (Pierce).
Equal amounts of denatured protein (40 g/lane) were loaded onto a
7.5% polyacrylamide gel and transferred to Immun-BlotTM polyvinylidene difluoride membrane (Bio-Rad) at 100 V for 1.5 h. The membranes
were blocked in 5% nonfat dry milk for 1 h and incubated with primary
antibody diluted in 5% bovine serum albumin overnight at 4 °C. The
primary antibodies against phosphorylated Akt (Ser473), phosphorylated IRS-1 (Ser307 and Ser612), phosphorylated p38 MAPK (Thr180/
Tyr182), phosphorylated ERK (Tyr183/185), phosphorylated JNK (Thr183/
Tyr185) and total Akt, IRS-1, p38 MAPK, ERK, and JNK were obtained
from Cell Signaling Technology. Anti-rabbit IgG conjugated with
horseradish peroxidase (Cell Signaling Technology) was used as the
secondary antibody, and the immunocomplexes were detected by
enhanced chemiluminescence (Pierce). Images were visualized with
film (Pierce) and quantified by densitometry using ImageQuant software (Amersham Biosciences).
PI 3-Kinase Assay—Rat hepatocytes were harvested with lysis buffer
containing 50 mM NaCl, 100 mM Tris, pH 8, 1% Triton X-100, 5 mM
EDTA, 10 mM NaF, 0.5 M NaVO4, 1 M dithiothreitol, and protease inhibitors. Equal amounts of protein (500 g) from each treatment group
were immunoprecipitated with anti-p85 antibody (Upstate Biotechnology) and protein A-Sepharose beads. The bead pellets were washed
twice with lysis buffer, once each with TNE buffer (200 mM Tris, pH 7.5,
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FIGURE 1. Arachidonic acid inhibits the insulin-mediated induction of G6PD mRNA
in primary rat hepatocytes. Rat hepatocytes were plated onto collagen-coated tissue
culture dishes in Hi/Wo/Ba medium plus 5% newborn calf serum. After 3– 4 h, the
medium was changed to serum-free medium and after 10 h Matrigel® was added. 24 h
post-isolation, the cells (3 plates/treatment) were treated with or without 0.04 M insulin ⫾ 175 M arachidonic acid or with arachidonic acid alone. After 24 h of treatment, the
cells were harvested, and total RNA was isolated. The top panel is a representative RNase
protection assay. The lower panel shows the results of two experiments (separate hepatocyte isolations) quantified using phosphorimaging and ImageQuant software. G6PD
mRNA was normalized to the amount of ␤-actin mRNA, and the results are expressed
relative to the amount of mRNA in no addition. NA, no addition; FA, arachidonic acid; Ins,
insulin.

100 mM NaCl, 1 mM EDTA) and 20 mM HEPES, pH 7.5, and suspended
in assay buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 0.2 mg/ml phosphoinositol, 60 M ATP, 20 Ci [␥-32P]ATP). After 15 min in assay
buffer, the reaction was terminated by the addition of 1 M HCl, and the
lipids were extracted with chloroform:methanol (1:1). The organic
phase was loaded on silica gel TLC plates (10). The lipids were visualized
using autoradiography.

RESULTS
Insulin Induces the Expression of G6PD mRNA, whereas Arachidonic
Acid Attenuates This Effect—Primary rat hepatocytes were used for
these studies, because they are the only cell culture system that mimics
the effects of dietary polyunsaturated fat on the regulation hepatic
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FIGURE 2. Arachidonic acid inhibits Akt activation and induces Ser307 phosphorylation of
IRS-1. Hepatocytes were treated with or without
arachidonic acid (175 M) 24 h prior to the addition
of insulin (0.04 M) and isolated 5, 10, 30, or 60 min
after the addition of insulin. A, Western blot analysis was performed against total and phosphorylated IRS-1 and Akt. The antibodies specifically
detected IRS-1 phosphorylated at Ser307 or Ser612
and Akt phosphorylated at Ser473. The asterisk
denotes a nonspecific band detected with the
IRS-1 Ser307 antibody. B, the amount of phosphorylated Akt in n ⫽ 4 experiments for the 5-, 10-,
and 30-min time points, and n ⫽ 3 experiments for
the 60 min. Each bar is the mean ⫾ S.E. for the indicated number of experiments, and the values are
expressed as the fold increase in phosphorylated
Akt relative to the amount in hepatocytes not
treated with insulin or arachidonic acid. C, the
amount of phosphorylated IRS-1 (Ser307) for n ⫽ 4
experiments for the 5-, 10-, and 30-min time
points, and n ⫽ 2 experiments for 60 min. The values are expressed relative to the amount of phosphorylated protein in hepatocytes not treated
with insulin or arachidonic acid. P-Akt, phosphorylated Akt; P-IRS-1, phosphorylated IRS-1; FA, arachidonic acid; I, insulin.
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G6PD expression. In hepatocytes, insulin increases G6PD mRNA abundance, and arachidonic acid inhibits G6PD mRNA amount, similar to
the changes in G6PD expression observed in intact liver, in animals fed
a high carbohydrate diet, and a diet supplemented with polyunsaturated
fat (6% safflower oil), respectively (6, 29). Furthermore, regulation of
G6PD expression occurs at a nuclear post-transcriptional step in both
intact liver and primary hepatocyte cultures (6, 28, 29). We first asked
whether arachidonic acid per se regulated G6PD expression. Because
G6PD activity is essential for cell viability, the amount of G6PD mRNA
remains readily detectable in the absence of insulin (Fig. 1). The addition
of arachidonic acid alone did not decrease the expression of G6PD
mRNA. In contrast, insulin induced G6PD mRNA expression 7-fold,
and arachidonic acid inhibited this induction by 50% or more. Thus,
arachidonic acid appears to inhibit the insulin-mediated induction of
G6PD expression.
Arachidonic Acid Inhibits Akt Phosphorylation and Induces Ser307
Phosphorylation of IRS-1—Because the arachidonate inhibition is only
observed in cells with intact insulin action, we hypothesized that arachidonic acid interferes with the PI 3-kinase pathway and thus prevents the
induction of G6PD mRNA by insulin. The induction of G6PD mRNA by
insulin has been demonstrated to require the PI 3-kinase signal transduction pathway (Ref. 30 and data not shown). The form or metabolite
of arachidonic acid that inhibits gene expression is not known. Thus, the
hepatocytes were pre-incubated with arachidonic acid to allow time for
incorporation of this fatty acid into membrane phospholipid and/or
generation of the relevant intracellular metabolite. The rapid signal
transduction by the insulin receptor could otherwise have preceded the
generation of the relevant inhibitory form of arachidonic acid. Insulin
induced Akt phosphorylation 24 –75-fold across time points (Fig. 2, A
and B). This induction was rapid and persisted through 60 min. Preincubation of hepatocytes with arachidonic acid attenuated the insulinmediated induction of Akt phosphorylation by 50 –72% across the time
points (Fig. 2, A and B). The amount of total Akt was not affected by
these treatments (Fig. 2A). Similarly, arachidonic acid inhibited PI 3-kinase activity by 50%, consistent with it being an upstream activator of
Akt (data not shown).
The decrease in Akt phosphorylation in cells incubated with arachidonic acid suggests that arachidonic acid is inhibiting a step at or prior
to PI 3-kinase activation. Because phosphorylation of IRS-1 at serines
can interfere with its interaction with either the insulin receptor or PI
3-kinase and thereby inhibits insulin signal transduction (12), we measured changes in the amount of IRS-1 phosphorylation on two different
serine residues. Incubation of hepatocytes with arachidonic acid prior to
and during the addition of insulin increased IRS-1 Ser307 phosphorylation 4 – 6-fold at each time point (Fig. 2, A and C). Insulin alone caused
a smaller but reproducible increase in Ser307 phosphorylation. Arachidonic acid does not cause an increase in the phosphorylation of all
regulatory serines in IRS-1. In this regard, arachidonic acid did not
stimulate an increase in phosphorylation at Ser612 of IRS-1 (Fig. 2A).
Although phosphorylation of Ser612 can also abolish tyrosine phosphorylation of IRS-1 (7), arachidonic acid inhibition of insulin signaling in
hepatocytes does not appear to involve this serine residue. These results
suggest that arachidonic acid increases Ser307 phosphorylation of IRS-1;
this in turn interferes with the PI 3-kinase activity and Akt phosphorylation, which are required for the insulin induction of G6PD mRNA.
Arachidonic Acid Induces p38 MAPK Phosphorylation—To explore
the mechanism for the increase in IRS-1 Ser307 phosphorylation, we
determined whether arachidonic acid in the presence of insulin activates serine/threonine kinases involved in serine phosphorylation of
IRS-1. Members of the MAP kinase family are known to stimulate serine
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phosphorylation of IRS-1 (15–20). The amounts of phosphorylated and
activated as well as the total amounts of the three MAP kinases, ERK,
JNK, and p38, were measured by Western blot analyses (Fig. 3, A and B).
Insulin stimulated a small but consistent increase in p38 MAPK phosphorylation. A similar increase was detected with arachidonic acid
alone (Fig. 3C). The greatest increase in the phosphorylation of p38
MAPK (4 – 6-fold) was observed with arachidonic acid in the presence
of insulin as compared with no additions. Furthermore, the increase in
p38 MAPK phosphorylation occurred within the same time frame as the
changes in Akt and IRS-1 Ser307 phosphorylation. The total amount of
p38 MAPK was not regulated by these treatments (Fig. 3C). In contrast,
arachidonic acid did not increase the amounts of activated ERK and
JNK. Fluctuations in ERK and JNK activation were observed across
treatments and likely reflect stimulation due to the manipulation of the
cells for the addition of the treatments. There was no consistent effect of
the treatments per se on ERK or JNK activation. This result suggests that
arachidonic acid stimulates Ser307 phosphorylation of IRS-1 by the activation of p38 MAPK.
Inhibition of the p38 MAPK Pathway Decreases the Arachidonic Acidmediated Inhibition of G6PD mRNA Expression—We next tested
whether the activation of p38 MAPK by arachidonic acid is responsible
for the inhibition of G6PD mRNA accumulation. The p38 MAP kinase
pathway was inhibited by SB203580. SB203580 had little or no effect on
the insulin-mediated induction of G6PD mRNA abundance but abrogated the inhibition by arachidonic acid (Fig. 4). In contrast, inhibition
of ERK signaling with the inhibitor PD98059 had no detectable effect on
G6PD regulation by insulin or arachidonic acid (data not shown), consistent with the lack of ERK activation by arachidonic acid. To verify that
activation of p38 MAPK was involved in the Ser307 phosphorylation of
IRS-1, the effects of arachidonic acid on Ser307 phosphorylation of IRS-1
and Akt phosphorylation were measured in hepatocytes incubated with
SB203580. Arachidonic acid in the presence of the p38 MAPK inhibitor
did not increase the Ser307 phosphorylation of IRS-1 as compared with
insulin- and SB203580-treated hepatocytes (Fig. 5, compare lanes 4 and
5 versus 2 and 3 for P-IRS1). At the same time, Akt phosphorylation in
hepatocytes incubated with arachidonic acid and SB203580 did not
decrease with respect to hepatocytes incubated with insulin and
SB203580 (Fig. 5, lanes 4 and 5 versus 2 and 3 for P-Akt). These results
are consistent with the idea that activation of p38 MAP kinase by arachidonic acid impairs the activation of the PI 3-kinase by inducing Ser307
phosphorylation of IRS-1, which in turn inhibits the induction of G6PD
mRNA by insulin.
Multiple Unsaturated Fatty Acids Inhibit Insulin Signal Transduction—Polyunsaturated fatty acids of both the 6 and 3 families
inhibit G6PD expression (6). We asked whether other polyunsaturated
fatty acids also inhibit insulin signal transduction. Eicosapentaenoic
acid (20:53) was as effective as arachidonic acid (20:46) at both
decreasing Akt phosphorylation and increasing p38 MAPK phosphorylation (TABLE ONE). The eighteen carbon precursors of these fatty
acids, especially linoleate (18:2), caused similar changes in Akt and p38
MAPK phosphorylation but were somewhat less effective, similar to the
lower inhibitory effect of these fatty acids on G6PD mRNA accumulation both historically (6) and in this experiment (data not shown).
TNF␣ Induces p38 MAP Kinase, Inhibits Activation of Akt, and Also
Diminishes Induction of G6PD by Insulin—To corroborate that arachidonic acid activation of p38 MAPK was involved in its inhibition of
G6PD expression, we tested the effect of another activator of p38
MAPK. TNF␣ inhibits insulin-mediated Akt phosphorylation in
3T3-L1 adipocyte myotubes (17, 20). In addition, TNF␣ activates p38
and other MAP kinases in various cell lines, resulting in inhibition of the
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FIGURE 3. Arachidonic acid activates p38 MAPK.
Hepatocytes were isolated and plated as
described in the legend to Fig. 1. Cell lysates were
prepared after 2, 5, 10, 30, and 60 min from
the untreated, insulin (0.04 M)-treated, or
insulin ⫹ arachidonic acid (175 M)-treated cells.
A, Western blot analysis was performed against
the phosphorylated and total forms of ERK, JNK,
and p38 MAP kinases. The antibodies for the phosphorylated MAP kinases recognize phosphates
at Tyr183/185, Thr183/Tyr185, and Thr180/Tyr182,
respectively. A representative blot of at least four
separate experiments is shown. B, quantitative
representation of the fold induction of phosphorylated p38 MAPK in hepatocytes treated with
insulin alone or insulin ⫹ arachidonic acid. Each
bar represents the mean ⫾ S.E., and the values are
expressed relative to the absence of treatment.
Repetition was as follows: n ⫽ 4 for 2 min, n ⫽ 6 for
5 min, n ⫽ 8 for 10 min, n ⫽ 4 for 30 min, and n ⫽ 2
for 60 min. C, hepatocytes were incubated with
insulin (0.4 M) alone, arachidonic acid (175 M)
alone, or insulin ⫹ arachidonic acid. Cell lysates
were prepared 5, 10, or 30 min later, and Western
blot analysis was performed against phosphorylated and total p38 MAPK. The blot is representative of n ⫽ 3 separate experiments. FA, arachidonic acid; P-p38, phosphorylated p38; P-ERK,
phosphorylated ERK; P-JNK, phosphorylated JNK; I,
insulin.
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TABLE ONE

Effect of various polyunsaturated fatty acids on Akt and p38 MAPK
phosphorylation
Rat hepatocytes were either pre-incubated with fatty acid for 24 h prior to the
addition of insulin (Akt-phosphorylation) or treated simultaneously with
insulin and 175 M fatty acid (p38 MAPK phosphorylation). Total cell lysates
were prepared 10 and 30 min after the addition of insulin. Total and phosphorylated Akt and p38 MAPK were determined by Western blot analysis. The
values are the ratio of phosphorylated to total Akt or p38 MAPK and are
expressed relative to insulin alone. The data are representative of n ⫽ 2 experiments that showed the same results. 18:2, linoleic acid; 18:3, linolenic acid;
20:5, eicosapentanoic acid; P-Akt, phosphorylated Akt; P-p38, phosphorylated
p38.
Treatments

FIGURE 4. A p38 MAPK inhibitor, SB203580, reverses the arachidonic acid-mediated
decrease of G6PD mRNA. Hepatocytes were treated with or without 10 M SB203580
for 1 h. After 1 h, arachidonic acid (175 M) was added, and 2 h later, insulin (0.04 M) was
added. After 12 h, the medium was replenished with one of the same composition. Total
RNA was isolated after 24 h with insulin. The isolated RNA was analyzed by RNase protection assay and quantified using phosphorimaging and ImageQuant software. The
values are the amount of G6PD mRNA normalized to the amount of ␤-actin mRNA and
are plotted relative to the amount of RNA in the absence of treatments or inhibitor. Each
bar represents the mean ⫾ S.E. of n ⫽ 3 experiments. I, insulin; FA, arachidonic acid.

10 minutes
Insulin
Insulin ⫹ 18:2
Insulin ⫹ 18:3
Insulin ⫹ 20:5
30 minutes
Insulin
Insulin ⫹ 18:2
Insulin ⫹ 18:3
Insulin ⫹ 20:5

P-Akt/Akt

P-p38/p38

100
52
33
26

1
2.3
1.6
11.1

100
82
36
11

1
6
18
35

DISCUSSION

FIGURE 5. Inhibition of p38 MAPK blocks the decrease in Akt activation and the
increase in IRS-1 Ser307 phosphorylation by arachidonic acid. Hepatocytes were
treated with or without arachidonic acid (175 M) for 23 h. The cells were then incubated
with or without 10 M SB203580 for 1 h, prior to the addition of insulin (0.04 M). Total cell
lysates were isolated 5 min after the addition of insulin. Western blot analysis was performed with antibodies against total and phosphorylated Akt and IRS-1. The antibody for
phosphorylated IRS-1 recognizes phosphate at Ser307, and the antibody for phosphorylated Akt recognizes phosphate at Ser473. FA, arachidonic acid; P-IRS-1, phosphorylated
IRS-1; P-Akt, phosphorylated Akt.

PI 3-kinase pathway (20). Incubation of rat hepatocytes with insulin and
TNF␣ resulted in a concomitant 5-fold increase in phosphorylated p38
MAPK and a 53–76% decrease in phosphorylated Akt across time
points (Fig. 6, A and B, respectively). These changes in p38 MAPK and
Akt phosphorylation occurred within the same time frame as the
changes caused by arachidonic acid. In addition, TNF␣ also decreased
the insulin induction of G6PD mRNA by 50% (Fig. 6C). Thus, activation
of MAP kinases by multiple effectors is associated with a decrease in Akt
activation and a decrease in the accumulation of G6PD mRNA.
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In previous work, we have defined a unique post-transcriptional
mechanism whereby polyunsaturated fatty acids inhibit G6PD expression, a decrease in pre-mRNA splicing (26, 31). In the present study, we
sought to determine the signaling pathway involved in this inhibition.
We demonstrated that the polyunsaturated fatty acid inhibition of
G6PD expression involves inhibition of the insulin-mediated induction
of G6PD (Fig. 1). This inhibition was a consequence of arachidonic acid
inhibition of insulin signal transduction via PI 3-kinase (Fig. 2). Incubation of hepatocytes with insulin and arachidonic acid activated p38
MAPK, resulting in Ser307 phosphorylation of IRS-1 (Figs. 2 and 3), a
modification that inhibits insulin activation of PI 3-kinase (7). In confirmation of this, inhibition of p38 MAPK activity blocks the arachidonic acid inhibition of G6PD expression, decreases Ser307 phosphorylation of IRS-1, and increases PI 3-kinase activity as measured by Akt
phosphorylation (Figs. 4 and 5). This is the first report of inhibition of a
lipogenic gene in liver via activation of the p38 MAPK pathway.
Polyunsaturated fatty acids have been demonstrated to activate MAP
kinases in various cell types (32–34). In primary rat hepatocytes, the action
of arachidonic acid is specific for p38 MAPK; extracellular signal-regulated
and c-Jun kinases are not activated by arachidonic acid (Fig. 3). Activation
of p38 MAPK is generally thought to be part of the stress-activated signal
transduction pathway (35, 36), and in this regard, arachidonic acid is a
known generator of toxic peroxides (37, 38). Several lines of evidence suggest that oxidative stress is not the mechanism by which arachidonic acid in
primary rat hepatocytes activates p38 MAPK. First, the extent of p38
MAPK activation was the same with either arachidonic acid or insulin alone
(Fig. 3C). In addition, arachidonic acid in the absence of insulin did not
inhibit G6PD expression, despite readily detectable levels of G6PD mRNA
(Fig. 1). Second, oxidation of arachidonic acid in the culture system was
minimized by the preparation of fatty acid stocks with butylated hydroxytoluene, and the culture medium was supplemented with additional ␣-tocopherol. Although these will not completely eliminate oxidation, peroxidation is not detectable using a thiobarbituric acid assay (6). More
importantly, enhanced oxidation induces G6PD expression (39, 40). Thus,
if arachidonic acid was causing oxidative stress, an increase in G6PD
expression would have been observed.
The mechanism by which arachidonic acid activates p38 MAPK is not
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FIGURE 6. TNF␣ inhibits activation of Akt, activates p38 MAPK, and inhibits induction of G6PD mRNA expression by insulin. A, hepatocytes were treated with or without insulin
(0.04 M) in the presence or absence of TNF␣ (10 ng/ml). Total cell lysates were isolated 5, 10, and 30 min after the addition of the treatments. Western blot analysis was performed
against the phosphorylated and total forms of ERK, JNK, and p38 MAP kinases. The antibodies for the phosphorylated MAP kinases recognize phosphates at Tyr183/185, Thr183/Tyr185,
and Thr180/Tyr182, respectively. B, hepatocytes were incubated with or without TNF␣ (10 ng/ml) for 24 h prior to the addition of insulin (0.04 M). Total cell lysates were isolated 5, 10,
and 30 min following the addition of insulin. Western blot analysis was performed with the antibody against the phosphorylated Akt (Ser473). The 5-min samples were from the same
experiment but on a separate gel from the other time points and were exposed on the same film. C, hepatocytes were treated with or without insulin (0.04 M) and TNF␣ (10 ng/ml)
as shown. After 24 h, total RNA was isolated, and the amounts of G6PD and ␤-actin mRNA were measured by RNase protection assay and imaged used phosphorimaging. All of the
figures are representative blots of n ⫽ 3 experiments. FA, arachidonic acid; P-Akt, phosphorylated Akt; P-p38, phosphorylated p38; P-ERK, phosphorylated ERK; P-JNK, phosphorylated
JNK.

clear. Multiple steps exist upstream of p38 MAPK and regulate its phosphorylation. Stress and cytokines generally induce p38 MAPK via Tak1 or
Ask1 (41, 42). Still, other reports suggest that protein kinase C is an important upstream kinase. Preliminary studies using the inhibitor of protein
kinase C, GF109203X, demonstrated that inhibition of protein kinase C
does not block the inhibition of G6PD expression by arachidonic acid.3
3

I. Talukdar and L. M. Salati, unpublished observations.
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Alternatively, polyunsaturated fatty acids can also activate AMP-activated
protein kinase in rat liver and hepatocytes (43, 44). Activation of AMPactivated protein kinase is associated with an increase in p38 MAPK phosphorylation in skeletal and cardiac muscles, and this increase is associated
with an increase in glucose uptake (45, 46). Although p38 MAPK has not
been shown to be a substrate for AMP-activated protein kinase, these
results are consistent with AMP-activated protein kinase being upstream in
the p38 MAPK signaling pathway.
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Arachidonic Acid Inhibits Insulin Signaling
The mechanism whereby arachidonic acid inhibits insulin signaling in
hepatocytes shares some of the characteristics of the mechanism of insulin
resistance caused by the consumption of a high fat diet. Diets with fat contents of 40% or more inhibit the activation of PI 3-kinase by increasing
Ser307 phosphorylation of IRS-1 (23). Activation of mammalian target of
rapamycin followed by subsequent activation of S6 kinase 1 was implicated
in this response (47, 48), and genetic ablation of the S6 kinase 1 gene protects against insulin resistance in the intact mouse (23). In primary hepatocytes, arachidonic acid did not activate S6 kinase 1, and treatment with
rapamycin for 1–24 h did not ablate the fatty acid inhibition.3 Still others
have implicated protein kinase C  in the Ser307 phosphorylation of IRS-1
and as a mechanism for fat-induced insulin resistance in skeletal muscle
(49). Although our preliminary data is inconsistent with protein kinase C
activation, this may reflect a distinct difference between isolated cells and
intact tissue. Alternatively, it may reflect distinctly different signal transduction pathways between muscle and liver.
Polyunsaturated fat inhibition of lipogenic gene expression occurs
with very low levels of dietary fat (6% by weight and 14% by kilocalorie
(29)). Such low levels of dietary fat are not associated with insulin resistance. The signal transduction mechanism that we described may reflect
a reversible response to changing nutrient conditions. In this regard, we
did not observe a decrease in total IRS-1 amount (Fig. 2A), even at longer
time points, which has been observed during insulin resistance (16, 17).
Regulation of hepatic metabolism by polyunsaturated fats must therefore occur at two levels: first, a reversible regulatory response, and second, under prolonged and excessive stimulus, a down-regulation of the
insulin signal transduction pathway.
What remains to be established is how these signals are translocated
to the nucleus and to the site of gene expression. In the case of G6PD, the
signals must activate proteins involved in pre-mRNA splicing. Cellular
signaling events regulate both positive and negative effectors of splicing.
The PI 3-kinase and MAP kinase pathways have been implicated in the
regulation of alternative splicing (50 –53). Insulin activates alternative
splicing of the protein kinase C ␤II mRNA via increased phosphorylation of the splicing activator SRp40 (51, 52). Involvement of p38 MAPK
signaling in shuttling of hnRNP A1, a suppressor of alternative splicing,
has also been reported (54). The mechanisms involved in regulating
G6PD pre-mRNA splicing are currently under investigation.
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